DBV Technologies | DBVT - Los Gastos Financieros De La Deuda

Precio De Mercado
19.80
Cambio Diario
0.46 2.38%
Mensual
-2.32%
Anual
132.12%
Q2 Expectativa
19.35




Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amarin USD 3K 5K 2024-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
DBV Technologies USD 461K 323.71K 2025-03
Esperion Therapeutics USD 22.64M 585K 2025-12
Galectin Therapeutics USD 1.27M 220K 2024-06
Halozyme Therapeutics USD 4.91M 615K 2025-12
Incyte USD 582K 10K 2025-12
Insmed USD 20.6M 217K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
PTC Therapeutics USD 50.58M 2.59B 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
United Therapeutics USD 3.1M 100K 2025-12